D.E. Shaw & Co’s Lipocine LPCN Stock Holding History

D.E. Shaw & Co’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-605	Closed	-$38K	–	3464
2016 Q4	$38K	Buy	+605	New	+$38.3K	﹤0.01%	3394
2016 Q1	–	Sell	-921	Closed	-$202K	–	3631
2015 Q4	$202K	Buy	+921	New	+$193K	﹤0.01%	3557

Other funds holding LPCN

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co's LPCN Position: Q1 2017 in Review

D.E. Shaw & Co sold out of Lipocine (LPCN) in Q1 2017, closing a stake of 605 shares — an estimated $38K sold.

D.E. Shaw & Co first reported a position in LPCN in Q4 2015 and held it in 2 quarters. The position peaked at $202K in Q4 2015. 50 funds tracked by Wall St. Rank hold LPCN as of Q1 2017.

D.E. Shaw & Co reported no remaining Lipocine position as of Q1 2017 after selling out during the quarter.
D.E. Shaw & Co sold 605 Lipocine shares in Q1 2017, an estimated $38K.
D.E. Shaw & Co first reported a position in Lipocine in Q4 2015 and held it in 2 quarters.
D.E. Shaw & Co's Lipocine position peaked at $202K in Q4 2015.
50 funds tracked by Wall St. Rank held Lipocine as of Q1 2017.

Based on D.E. Shaw & Co's 13F filing for Q1 2017, filed 15 May 2017.